CSTL 250117 45.00C (CSTL250117C45000) Stock Options, News & Quotes

US OptionsDetailed Quotes

CSTL250117C45000

Watchlist

0.15
0.000.00%

15min DelayClose Dec 26 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $40
Moomoo NewsDec 23 09:31 ET · Ratings
Analysts' Top Healthcare Picks: Lifecore Biomedical (LFCR), Castle Biosciences (CSTL)
TipRanksDec 23 09:01 ET · Ratings
Express News | Castle Biosciences Inc: Expects to Launch Pipeline Test by End of 2025
ReutersDec 23 07:07 ET
Castle Biosciences Highlights Progress for Its Pipeline Atopic Dermatitis Gene Expression Profile Test
BusinesswireDec 23 07:00 ET
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BusinesswireDec 19 07:00 ET
Express News | Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ReutersDec 19 07:00 ET

Comments

Stock_Drift

Oct 20 04:18

$Castle Biosciences (CSTL.US)$

Teddy123

Sep 29 21:15

New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients w

$Castle Biosciences (CSTL.US)$
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma | CSTL Stock News

Iwill TradeScared

Sep 3 11:38

$Castle Biosciences (CSTL.US)$

Iwill TradeScared

Aug 30 11:51

$Castle Biosciences (CSTL.US)$

Trytosaveabit

May 29 15:33

Nice!

$Castle Biosciences (CSTL.US)$ New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis 1 MINUTE AGO, 4:30 PM EDT VIA BUSINESSWIRE